On the other hand, intact NF-κB signaling is not only an essential pathway in many cancer entities, such as mucosa-associated gastric lymphoma, Hodgkin’s disease, and diffuse large-B-cell lymphoma, but can compromise the response to anticancer therapies (Schmitt 2003). The gene discussed is NFKB1; the disease is cancer.